Anti-glaucoma Drugs Market Analysis by Regions and Business Development By 2030 | Covid 19 Growth and Change

The Business Research Company offers “Antiglaucoma Drugs Global Market Report 2020-30: Covid 19 Impact And Recovery" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as it covers 60 geographies. The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by region and by country. It also compares the market’s historic and forecast growth, and highlights important trend s and strategies that players in the market can adopt.

The global antiglaucoma drugs market is expected to decline from $6.6 billion in 2019 to $5.2 billion in 2020 at a compound annual growth rate (CAGR) of -21.3%. The decline is mainly due to the COVID-19 outbreak and the measures to contain it. COVID-19 pandemic is affecting industries across the globe including the pharmaceutical sector. The restrictions on non-essential medical services including ophthalmology services coupled with slowed production of drugs due to extended factory closures in various countries, shortage of APIs and other chemicals, and rise in prices of key ingredients are the key factors for this decline. The market is then expected to recover and grow at a CAGR of 5% from 2021 and reach $8 billion in 2023.

Place a DIRECT PURCHASE ORDER of The Entire 140+ Pages Report @ https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=2419

The antiglaucoma drug market consists of sales of antiglaucoma drugs which are used in the treatment of glaucoma. Glaucoma is a disease in which the optic nerve is damaged resulting into irreversible loss of vision and it is often associated with increased pressure of the fluid in eye. The market comprises of segments such as alpha agonists, beta blockers, prostaglandins, combined medication and other. The market does not include the sale of biologics used for the treatment of glaucoma.

Anti-glaucoma drugs are facing the risk of patent expiration in the USA and Europe. For instance, travaprost and bimatoprost, which are used in the treatment of glaucoma, will lose its patent in 2021. This will result in the launch of generic form of the drugs that are priced lower than branded drugs thereby reducing the overall market growth.

Antiglaucoma Drugs Market Segmentation:
By product type:
1. Alpha Agonist
2. Beta Blockers
3. Prostaglandin Analogs
4. Combined Medication

By Disease Condition Type:
1.Open-Angle Glaucoma
2.Angle-Closure Glaucoma
3. Normal-Tension Glaucoma
4. Congenital Glaucoma

Browse Complete Report @ https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report

Few Points From Table Of Content
1. Executive Summary
2. Antiglaucoma Drugs Market Characteristics
3. Antiglaucoma Drugs Market Size And Growth
4. Antiglaucoma Drugs Market Segmentation
5. Antiglaucoma Drugs Market Regional And Country Analysis
……
26. Key Mergers And Acquisitions In The Antiglaucoma Drugs Market
27. Antiglaucoma Drugs Market Trends And Strategies
28. Product Pipeline Analysis
29. Antiglaucoma Drugs Market Future Outlook and Potential Analysis
30. Appendix

The report covers the trends and market dynamics of the Antiglaucoma Drugs Market in major countries - Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. The report also includes consumer surveys and various future opportunities for the market.

Request for a Sample Copy of This Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=2419&type=smp

Some of the key players involved in the Antiglaucoma Drugs Market are Aerie Pharmaceuticals, Inc, Allergan, Novartis AG, Abbott Healthcare, Johnson & Johnson

Contact Information:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 8897263534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow us on Blog: http://blog.tbrc.info/

About US:
The Business Research Company has published over 1000 industry reports, covering over 2500 market segments and 60 geographies. The reports draw on 150,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders. The reports are updated with a detailed analysis of the impact of COVID-19 on various markets after WHO declared COVID-19 as a pandemic.

This release was published on openPR.